Three giants lead Jiangsu, Zhejiang and Shanghai listed pharmaceutical companies sitting 50 varieties

Medicine network January 18 - In recent years, with the deepening reform and comprehensive promotion of the pharmaceutical industry, all over the region ushered in a dense "policy tide", structural differentiation is obviousMedicine is one of the important pillar industries in Jiangsu, Zhejiang and Shanghai, and its status is becoming more and more prominentShanghai Pharma, East China Pharmaceuticals, Fosun Pharma as the leading A-share listed pharmaceutical companies in Jiangsu, Zhejiang and Shanghai, a total of 50 varietiesAccording to data, Shanghai Pharma has 24 preparations and series sales of 100 million yuan, ginseng injection sales of more than 700 million yuan, sulphate chlorpyrifos tablets, dansanketone II sodium sulfonate injection sales are more than 400 million yuan; More than 100 million products have 7; Fosun Pharma has 19 preparations and series of sales of 100 million yuan, non-bustas tablets, calcium serophony sulphate and other products for the first time over 100 million, calf serum deprotein injection, but also prototype glutathione series and other products sales are more than 500 million yuanaccording to statistics, according to statistics, in January-September 2016, Shanghai pharmaceutical operating income has reached 90.517 billion yuan, the industry's leading, the annual revenue is expected to exceed 100 billion;Zhejiang Pharmaceuticals, Xinhecheng, East China Pharmaceuticals, Haizheng Pharmaceuticals and KangEnbei's net profit for the first nine months of 2016 exceeded that of the whole of 2015;research and development investment in the pharmaceutical industry is an important indicator to measure the future development of enterprises, in recent years, national policies strongly support research and development innovation, the level of research and development of pharmaceutical enterprises has been improvedData show that in January-June 2016, Fosun Pharma, Hengrui Pharmaceutical spending on research and development were nearly 500 million yuan, and in 2015, Fosun Pharmaceuticals, Hengrui Pharmaceuticals and Haizheng Pharmaceuticals all spent more than 800 million yuan in research and development, accounting for the highest proportion of revenue in the industrythe three major companies leading the listed pharmaceutical companies in Jiangsu, Zhejiang and Shanghai
Shanghai Pharmaceuticalin January-September 2016, Shanghai Pharmaceutical revenue of 90.517 billion yuan, up 14.52% YoYNet profit attributable to shareholders of listed companies was RMB2,457 million, up 12.78 percent year-on-yearThe pharmaceutical industry achieved operating income of RMB9,396 million, up 5.76% YoY and gross margin of 52.21%Of these, 60 key products achieved sales revenue of RMB5.185 billion, up 6.98 percent year-on-year, accounting for 5.18 percent of industrial sales revenue, and the average gross margin of key products was 69.11 percentIn 2015, sales revenue of 60 key varieties of Shanghai Pharma was RMB6.790 billion, up 12.52% YoY, with sales accounting for 57.43% of the industrial share and gross margin of 67.04% of key varietiesRevenue scored more than 100 million yuan in 24 products, the cardiovascular system accounted for 3 of the top five varieties, and the ginseng injection led the way with sales of 724 million yuan According to the data, Shanghai Pharma is expected to have sales revenue of more than 100 million yuan in 2016, there are 25 large varieties as of the end of 2015, according to the existing approval count, A total of 300 varieties of Shanghai Pharma were included in the "National Development and Reform Commission pricing range of low-cost drug list", of which, 210 varieties of Western medicine a total of 893 product regulations, 90 varieties of Traditional Chinese medicine a total of 205 product regulations Shanghai Pharmaceutical
research and development investment mainly covers chemical drugs, traditional Chinese medicine and biological products, including innovative drugs, generic drugs and secondary development of listed varieties Of these, 26.98 percent invested in innovative drug research and development, 23.46 percent to the first imitation, imitation drug research and development, 49.56 percent to the secondary development of existing products 110 invention patents were applied for, 51 patents were granted, and by the end of 2015, there were 267 invention patents In the first three quarters of 2016, new recombinant anti-CD20 human-derived monoclonal antibody injections, lacolaamine raw materials and tablets, niratlyator-based maltose iron raw materials and injections, sucrose sodium raw materials and injections, Lei Beirazole sodium intestinal tablets and other five varieties of clinical approval 9, thyroid powder declaration production approval 1, injection with recombinant anti-HER2 humanized monoclonal antibody composition and propylene chloramide aerosol declaration clinical approval 2 East China Pharmaceutical in the first half of 2016, East China Pharmaceutical revenue was RMB12.244 billion, with net profit attributable to the parent company of RMB823 million, of which the manufacturing industry achieved revenue of RMB2,975 million; East China Medicine to scientific research and market-centric, focusing on specialty, special drug use, is the most comprehensive variety, the largest production and sales of organ transplantation and diabetes drugs domestic enterprises, has formed a stable product echelon, sales of more than 100 million yuan of products have 7, in the field of immunotransplantation, diabetes, digestive tract and kidney disease treatment market share are maintained in the domestic manufacturers leading in addition to continuing to maintain the original diabetes, fermentation and bacteria powder, organ transplant immunosuppressive and digestive system and other four product areas of the advantages, will also actively strengthen the development of new products, focusing on the development and promotion of anti-tumor, super antibiotics, liver disease treatment and cardiovascular and other areas of competitive advantage According to data, in 2015, the total expenditure on research and development directly and indirectly by East China Pharmaceutical and Holding subsidiaries was RMB21,774.43 million, up 7.34% YoY, accounting for 6.71% of the Company's audited net assets and about 4.60% of operating income (pharmaceutical industry portion) East China, while continuing to consolidate and expand product development and process improvement in the field of immunosuppressants, diabetes and gastrointestinal drugs, focused on developing the field of anti-tumor drugs, accelerate the development of super antibiotics and cardiovascular drugs Research and development expenditure is mainly used to pay the technical services of the New Drug Research Institute of East China Pharmaceutical Group, patent services, payment of project expenses of other scientific research cooperative units, as well as the procurement of raw materials required for the approval of their own new drugs, product process improvement and pilot experimental research in 2015, has completed 5 production projects and 6 clinical projects of the registration declaration, with the East China Pharmaceutical Research Institute jointly declared the first dattomycin domestic production approval, in the new drug transfer from the Institute of New Drugs to datomycin, at the same time, is also on schedule before the market preparations The above-mentioned research and development projects, for the company's future rich product line, business performance continued to provide a foundation Fosun Pharmaceuticals in 2015, Fosun Pharma's revenue was RMB12.609 billion, up 4.85 percent Year-on-year, and net profit attributable to shareholders of listed companies was RMB2.460 billion, up 16.43% YoY Among them, pharmaceutical manufacturing and research and development achieved operating income of RMB8,935 million, up 21.78 percent YoY, and medical services realized operating income of RMB1,379 million, up 16.26 percent YoY The increase in revenue was due to revenue growth in manufacturing, medical services and equipment agency businesses Fosun Pharma continued to maintain steady growth in the pharmaceutical manufacturing and research and development sector, and sales of major core products in the field of cardiovascular system, metabolic and digestive systems, anti-infection and anti-tumor disease series maintained rapid growth, with sales of antimalarial series such as artemisinin in the field of anti-infection disease treatment increasing by about 125.92 percent over the previous year Among the new products, sales of non-bustas tablets in the field of cardiovascular disease treatment are growing rapidly in 2015, a total of 19 preparations and series sales of 100 million yuan, non-bustas tablets, calcium serophony sulfonate and other products for the first time over 100 million, calf serum deprotein injection, but also prototype glutathione series and other products sales of more than 500 million yuan Fosun Pharma continues to increase its investment in research and development, focusing on the development of biosimilars and innovative drugs In the first half of 2016, research and development costs in the pharmaceutical manufacturing and research and development segment were 24,254.5 million, accounting for 5% of the revenue of the pharmaceutical manufacturing and research and development segment In 2015, research and development expenditure was RMB67,035.8 million, up 18.75% YoY, of which RMB 53,758.51 million was spent on research and development in the pharmaceutical manufacturing and research and development sector, accounting for 6% of the revenue of the sector 161 new drugs, generics and biosimilars and vaccines as of the end of 2015 In 2015, one biotype 1 innovative drug, two class 2 biosimilars (second indication), two 1.1 class innovative drugs, and 10 new drugs of class 3.1 that have not yet been listed in China submitted clinical applications to the State Food and Drug Administration; In addition, Hubei Xinsheng's arginine raw material, second-leaf pharmaceutical injection with pyraxilin sodium shubatan sodium through the CFDA listing approval, Chongqing pharmaceutical friend's hydrochloric acid wenrafasin tablets through the FDA listing approval in 2015, 89 patent applications were filed in the Pharmaceutical Manufacturing and Research and Development sector, including 6 U.S patent applications, 4 European patent applications, 2 Japanese patent applications, 3 PCT applications, and 15 patents granted in the Pharmaceutical Manufacturing and Research and Development section of the Group, including: 9 invention patents (including 1 U.S patent) with the implementation of industry supervision, two-vote system, bidding system, so that pharmaceutical enterprises the original business model has been greatly affected Only through research and development innovation, in order to provide sustained impetus for the steady and benign development of enterprises, and constantly enhance the core competitiveness Source: Annual Report of Listed Companies, Quarterly Report, Oriental Wealth Network